{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.06","upperLimit":"15.38","value":"9.76"},{"comment":"Data not estimable. Death due to any cause occurred in 3 patients (as reported at both data cuts). The median and upper limit were not reached due to too few events","groupId":"OG001","lowerLimit":"6.83","upperLimit":"NA","value":"NA"},{"comment":"Data not estimable. Death due to any cause occurred in 1 patient; the patient had a survival time of 3.15 months.The median and upper limit were not reached due to too few events","groupId":"OG002","lowerLimit":"3.15","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Overall survival was defined as the time in months from initiation of therapy to death due to any cause. Patients still alive at the end of the study, or lost to follow up, were censored at last day known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg.","id":"OG000","title":"Cohort 1a, Melflufen 40 mg"},{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg.","id":"OG001","title":"Cohort 1b, Melflufen 30 mg"},{"description":"Patients with severe renal impairment (eGFR ≥15 to \\<30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg.","id":"OG002","title":"Cohort 2a, Melflufen 20 mg"}],"paramType":"MEDIAN","populationDescription":"This analysis was performed in the Safety Analysis Set, which is defined as all patients who received at least 1 or partial dose of melflufen or dexamethasone.","reportingStatus":"POSTED","timeFrame":"Patients were followed for overall survival until death or until the last patient in the study had documented progression (confirmed on 2 consecutive assessments) or initiation of subsequent therapy (maximum of 39.2 months).","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}